A study to rank different dosages of antigen of GlaxoSmithKline (GSK) Biologicals’ investigational Respiratory Syncytial Virus (RSV) vaccine (GSK3003891A), based on their immune response and safety, when administered to healthy adult women.

Registry ID

EUCTR2016-001135-12

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

GlaxoSmithKline Biologicals

Start date

2016-10-11

Completion date

2018-02-05

Last update

2026-08-16

Conditions

• Respiratory Syncytial Virus

Summary

To rank different formulations of the investigational RSV vaccine based on safety/reactogenicity and immunogenicity data up to 1 month post-vaccination (Day 30).

Locations

• , , Belgium
• , , Germany
• , , Estonia
• , , France

Related clinical trials

• A Post-marketing Surveillance Study of Beyfortus (Nirsevimab) in Republic of Korea
• Assessing Antiviral Treatments in Early Symptomatic RSV
• A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Respiratory Syncytial Virus Vaccine

View on source registry